# A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

> **NCT04155125** · PHASE3 · COMPLETED · sponsor: **PT Kalbe Genexine Biologics** · enrollment: 391 (actual)

## Conditions studied

- Anaemia Associated With Chronic Kidney Disease

## Interventions

- **DRUG:** efepoetin alfa
- **DRUG:** Mircera

## Key facts

- **NCT ID:** NCT04155125
- **Lead sponsor:** PT Kalbe Genexine Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-02
- **Primary completion:** 2022-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155125, "A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04155125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*